| Literature DB >> 35989164 |
Mizuho Fukushige1, Ling-Shang Syue2, Kazuya Morikawa3, Wen-Liang Lin4, Nan-Yao Lee5, Po-Lin Chen5, Wen-Chien Ko6.
Abstract
BACKGROUND: Variable control measures for vancomycin-resistant Enterococcus (VRE) infections were adopted among different hospitals and areas. We investigated the burden and patient characteristics of healthcare-associated VRE infections in 2018-2019 and 2020, when multiple preventive measures for COVID-19 were taken.Entities:
Keywords: COVID-19; Enterococcus; Healthcare-associated infections; Prevention measures; Taiwan; Vancomycin resistance
Year: 2022 PMID: 35989164 PMCID: PMC9357275 DOI: 10.1016/j.jmii.2022.08.003
Source DB: PubMed Journal: J Microbiol Immunol Infect ISSN: 1684-1182 Impact factor: 10.273
The incidence density of healthcare-associated infections (HAIs), vancomycin-resistant Enterococcus (VRE) HAIs, and variables that related to the characteristics of the study hospital from 2018 to 2020.
| Variables (monthly) mean ± standard deviation | Year | F value | |||
|---|---|---|---|---|---|
| 2018 | 2019 | 2020 | |||
| Patient days | 32,891 ± 1927 | 33,238 ± 1816 | 31,666 ± 1509 | 2.64 | 0.086 |
| Case mix index | 1.422 ± 0.046 | 1.418 ± 0.055 | 1.374 ± 0.023 | 6.84 | 0.006 |
| Incidence density (‰) | |||||
| Overall HAIs | 3.77 ± 0.33 | 3.32 ± 0.44 | 3.33 ± 0.28 | 6.09 | 0.006 |
| MRSA HAIs | 0.07 ± 0.06 | 0.10 ± 0.06 | 0.05 ± 0.03 | 2.27 | 0.119 |
| VRE HAIs | 0.22 ± 0.09 | 0.24 ± 0.08 | 0.28 ± 0.07 | 1.86 | 0.172 |
| VRE HABSIs | 0.13 ± 0.07 | 0.12 ± 0.06 | 0.18 ± 0.07 | 2.34 | 0.112 |
| 48-h response rate (%) | 77.5 ± 9.3 | 74.6 ± 10.4 | 75.6 ± 7.9 | 0.30 | 0.741 |
HABSI, healthcare-associated bloodstream infection; MRSA, methicillin-resistant Staphylococcus aureus.
Figure 2The relative changes of several variables associated with healthcare-associated vancomycin-resistant Enterococcus bloodstream infections from 2018 to 2020. The data in 2019 are regarded as the reference value. The annual hospital-wide consumption/compliance data of parenteral vancomycin, third-generation cephalosporins, sodium hypochlorite, 75% alcohol, 4% chlorhexidine, N95 mask, surgical mask, and hand hygiene compliance rate were used for analyses. Note: 48h RR = 48-h response rate; HHC = hand hygiene compliance rate; CCI = Charlson comorbidity index score; VAN = vancomycin; 3 GC = third-generation cephalosporins; NaOCI = sodium hypochlorite; ALC = 75% alcohol, N95 = N95 mask, MSK = surgical mask, and CHX = 4% chlorhexidine.
Figure 1The monthly consumption quantity of disinfection agents and antimicrobial agents from 2018 to 2020. A) average monthly consumption of 75% alcohol (ALC), 4% chlorhexidine (CHX), and chlorhexidine-alcohol solutions (CHX-ALC) from 2018 to 2020. B) average monthly consumption of different types or class of antibiotics. Note: VAN = vancomycin; TZP = piperacillin/tazobactam; FEP = cefepime; 3 GC = third-generation cephalosporins; FQ_IV = intravenous fluoroquinolone. ∗∗: p < 0.001; ∗: p < 0.005.
Clinical characteristics and numbers of patients with healthcare-associated bacteremia due to vancomycin-resistant Enterococcus from 2018 to 2020.
| Patients' characteristics and comorbidities | Year | |||
|---|---|---|---|---|
| 2018 | 2019 | 2020 | ||
| Age range (mean), years | 39-93 (68) | 16-91 (67) | 20-94 (69) | 0.812 |
| Male sex (%) | 28 (51) | 26 (55) | 41 (62) | 0.671 |
| ICU stay (%) | 21 (41) | 12 (26) | 24 (36) | 0.251 |
| Hospital stay before VRE isolation, range (mean), days | 3-467 (36) | 6-261 (33) | 4-213 (32) | 0.891 |
| Charlson comorbidity index, range (mean) | 0-16 (5.7) | 0-10 (5.7) | 0-11 (5.3) | 0.643 |
| Comorbidities (%) | ||||
| Diabetes mellitus without end organ damage/complications | 24 (47) | 17 (36) | 24 (36) | 0.426 |
| Diabetes mellitus with end organ damage/complications | 2(4) | 0 (0) | 2 (3) | 0.418 |
| Metastatic tumor | 20 (39) | 17 (36) | 22 (33) | 0.805 |
| Moderate to severe renal disease | 16 (31) | 14 (30) | 16 (24) | 0.696 |
| Peptic ulcer disease | 14 (27) | 6 (13) | 6 (9) | 0.021 |
| Chronic pulmonary disease | 10 (20) | 15 (32) | 12 (18) | 0.189 |
| Congestive heart failure | 9 (17) | 11 (23) | 16 (24) | 0.670 |
| Cerebrovascular disease | 9 (18) | 5 (11) | 7 (11) | 0.460 |
| Dementia | 4 (8) | 6 (13) | 5 (8) | 0.594 |
| Tumor without metastasis | 4 (8) | 7 (15) | 10 (15) | 0.442 |
| Mild liver disease | 4 (8) | 5 (11) | 9 (14) | 0.608 |
| Moderate to severe liver disease | 3 (6) | 9 (19) | 6 (9) | 0.090 |
| Peripheral vascular disease | 3 (6) | 0 (0) | 3 (5) | 0.266 |
| Leukemia | 3 (6) | 3 (6) | 11 (17) | 0.094 |
| Hemiplegia | 2 (4) | 0 (0) | 4 (6) | 0.237 |
| Transplantation | 2 (4) | 2 (4) | 2 (3) | 0.936 |
| Myocardial infarction | 2 (4) | 2 (4) | 3 (5) | 0.986 |
| Connective tissue disease | 1 (2) | 2 (4) | 3 (5) | 0.736 |
| Lymphoma | 1 (2) | 4 (9) | 1 (2) | 0.110 |